Bactobyte LTD

we are developing a novel technology aiming to reduce the burden of infection disease by enabling a new standard in antibiotic administration. our product is a rapid, precise, and cost-effective antibiotics susceptibility analysis system, eliminating the need for petri dish-based testing in clinical laboratory. bactosense introduces a unique mechanism of action providing the shortest total time to result (tttr) of 2-8 hours as an alternative to the current golden standard of 3-5 days. the outcomes are decreased mortality rates, hospital and intensive care unit los (length of stay) and major cost avoidance.